MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100409-PIP01-21) and to the deferral

MHRA-100409-PIP01-21-M01

Scope of the Application

Active Substance(s)

autologous dendritic cells pulsed with autologous tumour cell lysate

Condition(s)

Treatment of high grade glioma

Pharmaceutical Form(s)

Cell suspension for injection

Route(s) of Administration

INTRADERMAL USE

Name / Corporate name of the PIP applicant

Northwest Biotherapeutics Inc.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Northwest Biotherapeutics Inc. submitted to the licensing authority on 26/07/2023 16:30 BST an application for a Modification

The procedure started on 02/08/2023 16:59 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100409-PIP01-21-M01

Of 24/08/2023 16:06 BST

On the adopted decision for autologous dendritic cells pulsed with autologous tumour cell lysate (MHRA-100409-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for autologous dendritic cells pulsed with autologous tumour cell lysate, Cell suspension for injection , INTRADERMAL USE .

This decision is addressed to Northwest Biotherapeutics Inc. , 4800 Montgomery Avenue, Bethseda, UNITED STATES OF AMERICA, MD 20814

ANNEX I

1. Waiver

1.1 Condition:

Treatment of high grade glioma The waiver applies / applied to: Paediatric Subset(s): The paediatric population weighing less than 6 kg body weight Pharmaceutical form(s): Cell suspension for injection Route(s) of administration: Intradermal use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of high grade glioma

2.2 Indication(s) targeted by the PIP:

Adjuvant treatment of high grade glioma after tumour resection and/or standard of care therapy

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 kg body weight to less than 18 years of age

2.4 Pharmaceutical Form(s):

Cell suspension for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 1 Open-label, single-arm study to assess the safety and efficacy of autologous dendritic cells pulsed with autologous tumour cell lysate (DCVax-L) in male and female children and adolescents weighing at least 6 kg to less than 18 years of age with recurrent resectable glioblastoma. Study 2 Open-label, single-arm study to assess the safety and efficacy of DCVax-L in male and female children and adolescents weighting at least 6 kg to less than 18 years of age with newly diagnosed resectable glioblastoma.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/07/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes